To prove the suitability of our cohort of patients for detecting differences in TNF ligand superfamily members in PDAC-patients and healthy controls, we first analyzed concentrations of APRIL, which is known to be deregulated in pancreatic cancer in a smaller subgroup of our cohort. This evidence concerns the gene TNFSF13 and familial pancreatic carcinoma.